344 related articles for article (PubMed ID: 26537529)
1. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
[TBL] [Abstract][Full Text] [Related]
2. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
Brümmendorf TH; Cortes JE; de Souza CA; Guilhot F; Duvillié L; Pavlov D; Gogat K; Countouriotis AM; Gambacorti-Passerini C
Br J Haematol; 2015 Jan; 168(1):69-81. PubMed ID: 25196702
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Gambacorti-Passerini C; Cortes JE; Lipton JH; Kantarjian HM; Kim DW; Schafhausen P; Crescenzo R; Bardy-Bouxin N; Shapiro M; Noonan K; Leip E; DeAnnuntis L; Brümmendorf TH; Khoury HJ
Haematologica; 2018 Aug; 103(8):1298-1307. PubMed ID: 29773593
[TBL] [Abstract][Full Text] [Related]
4. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
Cortes JE; Khoury HJ; Kantarjian HM; Lipton JH; Kim DW; Schafhausen P; Matczak E; Leip E; Noonan K; Brümmendorf TH; Gambacorti-Passerini C
Am J Hematol; 2016 Dec; 91(12):1206-1214. PubMed ID: 27531525
[TBL] [Abstract][Full Text] [Related]
5. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Gambacorti-Passerini C; Brümmendorf TH; Kim DW; Turkina AG; Masszi T; Assouline S; Durrant S; Kantarjian HM; Khoury HJ; Zaritskey A; Shen ZX; Jin J; Vellenga E; Pasquini R; Mathews V; Cervantes F; Besson N; Turnbull K; Leip E; Kelly V; Cortes JE
Am J Hematol; 2014 Jul; 89(7):732-42. PubMed ID: 24711212
[TBL] [Abstract][Full Text] [Related]
6. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Cortes JE; Kantarjian HM; Brümmendorf TH; Kim DW; Turkina AG; Shen ZX; Pasquini R; Khoury HJ; Arkin S; Volkert A; Besson N; Abbas R; Wang J; Leip E; Gambacorti-Passerini C
Blood; 2011 Oct; 118(17):4567-76. PubMed ID: 21865346
[TBL] [Abstract][Full Text] [Related]
8. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
9. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
Hochhaus A; Gambacorti-Passerini C; Abboud C; Gjertsen BT; Brümmendorf TH; Smith BD; Ernst T; Giraldo-Castellano P; Olsson-Strömberg U; Saussele S; Bardy-Bouxin N; Viqueira A; Leip E; Russell-Smith TA; Leone J; Rosti G; Watts J; Giles FJ;
Leukemia; 2020 Aug; 34(8):2125-2137. PubMed ID: 32572189
[TBL] [Abstract][Full Text] [Related]
10. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
[TBL] [Abstract][Full Text] [Related]
11. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Cortes JE; Kim DW; Kantarjian HM; Brümmendorf TH; Dyagil I; Griskevicius L; Malhotra H; Powell C; Gogat K; Countouriotis AM; Gambacorti-Passerini C
J Clin Oncol; 2012 Oct; 30(28):3486-92. PubMed ID: 22949154
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
Chuah C; Koh LP; Numbenjapon T; Zang DY; Ong KH; Do YR; Ohkura M; Ono C; Viqueira A; Cortes JE; Brümmendorf TH
Int J Hematol; 2021 Jul; 114(1):65-78. PubMed ID: 33851349
[TBL] [Abstract][Full Text] [Related]
13. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Khoury HJ; Cortes JE; Kantarjian HM; Gambacorti-Passerini C; Baccarani M; Kim DW; Zaritskey A; Countouriotis A; Besson N; Leip E; Kelly V; Brümmendorf TH
Blood; 2012 Apr; 119(15):3403-12. PubMed ID: 22371878
[TBL] [Abstract][Full Text] [Related]
14. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
Keller G; Schafhausen P; Brummendorf TH
Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
[TBL] [Abstract][Full Text] [Related]
15. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C
Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751
[TBL] [Abstract][Full Text] [Related]
16. Bosutinib for the treatment of chronic myeloid leukemia.
Doan V; Wang A; Prescott H
Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.
Trask PC; Cella D; Besson N; Kelly V; Masszi T; Kim DW
Leuk Res; 2012 Apr; 36(4):438-42. PubMed ID: 22036634
[TBL] [Abstract][Full Text] [Related]
18. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
[TBL] [Abstract][Full Text] [Related]
20. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
